Cannabis use in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials (RCTs).

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Irish Journal of Medical Science Pub Date : 2025-01-17 DOI:10.1007/s11845-024-03844-w

Rayyan Vaid, Areeba Fareed, Rabia Qader, Aariz Hussain, Wajiha Shaikh, Ushna Zameer, Sidhant Ochani

{"title":"Cannabis use in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials (RCTs).","authors":"Rayyan Vaid, Areeba Fareed, Rabia Qader, Aariz Hussain, Wajiha Shaikh, Ushna Zameer, Sidhant Ochani","doi":"10.1007/s11845-024-03844-w","DOIUrl":null,"url":null,"abstract":"Objective: This meta-analysis aims to systematically evaluate the efficacy and safety of cannabis in the management of Crohn's disease (CD) by synthesizing evidence from randomized controlled trials (RCTs). By adhering to the 2020 PRISMA guidelines and registering the study protocol with PROSPERO, this research intends to offer robust, evidence-based recommendations for healthcare practitioners on the therapeutic potential and clinical implications of cannabis use in CD management.Methods: A literature search encompassing PubMed, Google Scholar, and the Cochrane Library was conducted to identify relevant RCTs comparing cannabis to placebo or standard therapy in CD patients. Inclusion criteria focused on outcomes such as remission rates, C-reactive protein (CRP) levels, quality of life (QoL), and adverse events (AEs). Statistical analysis using RevMan 5.3 involved weighted mean differences (MD) and 95% confidence intervals to compare outcomes between the cannabis and control groups.Results: The meta-analysis revealed significant findings regarding the impact of cannabis on CD management. The cannabis group exhibited significantly higher clinical remission rates at 8 weeks compared to the control group, with low heterogeneity [MD = - 67.98; 95% CI: (- 100.68, - 35.29)]. However, a statistically significant improvement in QoL was observed in the placebo group compared to the cannabis-treated group [MD = 19.62; 95% CI (14.24 to 25.00)]. There was a non-significant lowering in serum CRP levels compared to the placebo group [MD: - 0.51; 95% CI: (- 1.05, 0.02)].Conclusion: The study concludes that cannabis shows promise as a therapeutic option for CD, demonstrating higher remission rates and potential benefits for disease management. However, it also highlights the need for larger, standardized research studies to solidify conclusions regarding efficacy, safety, and biomarker responses in CD patients.","PeriodicalId":14507,"journal":{"name":"Irish Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Irish Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11845-024-03844-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This meta-analysis aims to systematically evaluate the efficacy and safety of cannabis in the management of Crohn's disease (CD) by synthesizing evidence from randomized controlled trials (RCTs). By adhering to the 2020 PRISMA guidelines and registering the study protocol with PROSPERO, this research intends to offer robust, evidence-based recommendations for healthcare practitioners on the therapeutic potential and clinical implications of cannabis use in CD management.

Methods: A literature search encompassing PubMed, Google Scholar, and the Cochrane Library was conducted to identify relevant RCTs comparing cannabis to placebo or standard therapy in CD patients. Inclusion criteria focused on outcomes such as remission rates, C-reactive protein (CRP) levels, quality of life (QoL), and adverse events (AEs). Statistical analysis using RevMan 5.3 involved weighted mean differences (MD) and 95% confidence intervals to compare outcomes between the cannabis and control groups.

Results: The meta-analysis revealed significant findings regarding the impact of cannabis on CD management. The cannabis group exhibited significantly higher clinical remission rates at 8 weeks compared to the control group, with low heterogeneity [MD = - 67.98; 95% CI: (- 100.68, - 35.29)]. However, a statistically significant improvement in QoL was observed in the placebo group compared to the cannabis-treated group [MD = 19.62; 95% CI (14.24 to 25.00)]. There was a non-significant lowering in serum CRP levels compared to the placebo group [MD: - 0.51; 95% CI: (- 1.05, 0.02)].

Conclusion: The study concludes that cannabis shows promise as a therapeutic option for CD, demonstrating higher remission rates and potential benefits for disease management. However, it also highlights the need for larger, standardized research studies to solidify conclusions regarding efficacy, safety, and biomarker responses in CD patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

大麻在克罗恩病中的使用：随机对照试验（rct）的系统回顾和荟萃分析。

目的：本荟萃分析旨在通过综合随机对照试验（RCTs）的证据，系统评价大麻治疗克罗恩病（CD）的有效性和安全性。通过遵守2020年PRISMA指南并在PROSPERO注册研究方案，本研究旨在为医疗从业者提供关于大麻在CD管理中的治疗潜力和临床意义的强有力的、基于证据的建议。方法：对PubMed、谷歌Scholar和Cochrane图书馆进行文献检索，以确定比较大麻与安慰剂或标准治疗对CD患者的相关随机对照试验。纳入标准主要关注缓解率、c反应蛋白（CRP）水平、生活质量（QoL）和不良事件（ae）等结果。使用RevMan 5.3进行统计分析，采用加权平均差异（MD）和95%置信区间来比较大麻组和对照组之间的结果。结果：荟萃分析揭示了大麻对CD管理影响的重要发现。与对照组相比，大麻组在8周时表现出明显更高的临床缓解率，异质性低[MD = - 67.98；95% ci:(- 100.68, - 35.29)]。然而，与大麻治疗组相比，安慰剂组的生活质量有统计学意义的改善[MD = 19.62；95% CI(14.24 ~ 25.00)]。与安慰剂组相比，血清CRP水平无显著降低[MD: - 0.51；95% ci:(- 1.05, 0.02)]。结论：该研究得出结论，大麻有望作为乳糜泻的治疗选择，显示出更高的缓解率和疾病管理的潜在益处。然而，它也强调了需要更大的、标准化的研究来巩固关于乳糜泻患者的疗效、安全性和生物标志物反应的结论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Irish Journal of Medical Science 医学-医学：内科

CiteScore

3.70

自引率

4.80%

发文量

357

审稿时长

4-8 weeks

期刊介绍： The Irish Journal of Medical Science is the official organ of the Royal Academy of Medicine in Ireland. Established in 1832, this quarterly journal is a contribution to medical science and an ideal forum for the younger medical/scientific professional to enter world literature and an ideal launching platform now, as in the past, for many a young research worker. The primary role of both the Academy and IJMS is that of providing a forum for the exchange of scientific information and to promote academic discussion, so essential to scientific progress.